Nutraceutical composition comprising inulin for treating and preventing ocular disorders or intestinal microbiota imbalance
US-2024165149-A1 · May 23, 2024 · US
Agent for treating or preventing cancer, and combination of RF pathway inhibitor and MEK inhibitor for treating or preventing cancer
US11925646B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11925646-B2 |
| Application number | US-202217680972-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 25, 2022 |
| Priority date | Feb 26, 2021 |
| Publication date | Mar 12, 2024 |
| Grant date | Mar 12, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a method for treatment or prevention of cancer through novel action mechanism, namely, through inhibition of a riboflavin pathway. The method for treatment or prevention of cancer comprises administering an RF pathway inhibitor to a subject in need thereof.
First claim
Opening claim text (preview).
We claim: 1. A method for treatment of pancreatic cancer comprising administering an effective amount of roseoflavin to a subject. 2. The method according to claim 1 , further comprising administering an effective amount of trametinib to the subject. 3. The method of claim 1 wherein the effective amount of roseoflavin is administered alone as a sole pharmaceutically active ingredient. 4. The method of claim 1 wherein the subject is a human.
Assignees
Inventors
Classifications
- A61K31/525Primary
Isoalloxazines, e.g. riboflavins, vitamin B2 · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11925646B2 cover?
- The present invention provides a method for treatment or prevention of cancer through novel action mechanism, namely, through inhibition of a riboflavin pathway. The method for treatment or prevention of cancer comprises administering an RF pathway inhibitor to a subject in need thereof.
- Who is the assignee on this patent?
- Univ Hokkaido Nat Univ Corp, Tsuzuki Educational Inst, National Univ Corp Hokkaido Univ
- What technology area does this patent fall under?
- Primary CPC classification A61K31/525. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).